Extended Release Amantadine Tablet for Sleep-Friendly Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current amantadine formulations, particularly immediate release forms, cause dose-related CNS side effects like insomnia and sleep disturbances, limiting their administration to before 4 pm to minimize these issues, and there is a need for a formulation that provides effective plasma concentrations upon waking without disrupting sleep.
Innovation Solution
Development of an extended release amantadine composition allowing administration less than three hours before bedtime, which gradually increases plasma concentrations, providing optimal levels in the morning while minimizing nighttime interference and reducing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immediate release amantadine is administered to achieve therapeutic plasma concentrations, then Parkinson's disease symptoms are treated, but insomnia and sleep disturbance side effects occur
Solution Approach 1:
The patent segments the drug release into two distinct phases: an initial release phase providing rapid therapeutic effect, and a sustained release phase maintaining plasma concentrations without peak-related side effects. This is achieved through a dual-layer tablet structure with different release characteristics, separating the therapeutic function from the harmful stimulant effect.
Solution Approach 2:
The patent implements dynamic release characteristics where the tablet provides different release rates at different time points. The initial phase delivers higher concentrations for symptom control, while the later phase provides gradual, sustained release that avoids insomnia. The release profile adapts to the patient's needs throughout the day.
2Object-generated harmful factors
If amantadine is administered before 4 pm to minimize sleep disturbance, then side effects are reduced, but plasma concentrations are low in the morning
Solution Approach 1:
The patent employs preliminary action by providing an initial dose during the day that establishes therapeutic plasma concentrations before bedtime. The sustained release mechanism then maintains these concentrations through the night and into the morning, ensuring adequate drug levels are already present when the patient wakes up, eliminating the need for morning dosing.
Solution Approach 2:
The patent ensures continuity of useful action through sustained release mechanisms that maintain therapeutic plasma concentrations continuously from the initial dose through the night and into the morning. This continuous availability of the drug at therapeutic levels addresses both the sleep disturbance issue and the morning concentration requirement.
3Quantity of substance
If extended release formulation is administered to maintain plasma concentrations, then morning levels are improved, but complexity of formulation increases
Solution Approach 1:
The patent merges two different release mechanisms into a single integrated tablet structure. The dual-layer design combines an initial release component and a sustained release component into one dosage form, achieving complex plasma concentration profiles through a relatively simple structural integration rather than multiple separate formulations.
Data Source
AI summary
Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.